Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,444 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,444 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00037882 | PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of… | Phase 2 | terminated | May 27, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00038415 | A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a… | Phase 1 / Phase 2 | terminated | May 31, 2002 | M.D. Anderson Cancer Center | Vaccine unavailable. | Other (stated, no rule matched) |
| NCT00038805 | Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute… | Phase 2 / Phase 3 | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00043810 | Study of Gelonin Purging of Autologous Stem Cells for Transplantation | Phase 1 / Phase 2 | terminated | Aug 15, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00048100 | Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes | Phase 1 | terminated | Oct 25, 2002 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT00038779 | Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure… | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | Lack of Accrual | Enrollment / accrual |
| NCT02755480 | Ultralow Dose Thoracic Computed Tomography in Immunocompromised Patients(ULDCT-IC) | N/A | terminated | Apr 29, 2016 | University Health Network, Toronto | PI has left UHN. This study is no longer running at UHN. | Other (stated, no rule matched) |
| NCT01904643 | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or… | Phase 1 | terminated | Jul 22, 2013 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00038870 | Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes | N/A | withdrawn | Jun 7, 2002 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT02992860 | Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED…(SAMBA) | Phase 2 | terminated | Dec 14, 2016 | GWT-TUD GmbH | Enrollement was stopped due to a recommendation by the IDMC/FDA for a parallel clinical trial with… | Enrollment / accrual |
| NCT03207334 | iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) | Phase 2 | withdrawn | Jul 2, 2017 | University of Florida | Insufficient funding | Funding |
| NCT02641002 | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk… | Phase 1 | terminated | Dec 29, 2015 | Celgene | Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a… | Other (stated, no rule matched) |
| NCT02469415 | Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | Phase 2 | terminated | Jun 11, 2015 | M.D. Anderson Cancer Center | FDA Clinical Hold | Other (stated, no rule matched) |
| NCT01866553 | Nilotinib Plus Pegylated Interferon-α2b in CML | Phase 2 | terminated | May 31, 2013 | Amsterdam UMC, location VUmc | insufficient enrollment | Enrollment / accrual |
| NCT02057770 | Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide… | Phase 1 | terminated | Feb 7, 2014 | Washington University School of Medicine | Low accrual rate | Enrollment / accrual |
| NCT00038649 | Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and… | Phase 2 | terminated | Jun 4, 2002 | M.D. Anderson Cancer Center | Sponsor discontinued providing study drug. | Other (stated, no rule matched) |
| NCT02302846 | Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML)… | Phase 2 | terminated | Nov 27, 2014 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01846624 | Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid… | Phase 2 | terminated | May 3, 2013 | David Iberri | Accrual factor | Enrollment / accrual |
| NCT02415608 | Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis | Phase 2 | terminated | Apr 14, 2015 | Jason Robert Gotlib | Slow accrual | Enrollment / accrual |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00398047 | Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating… | Phase 2 | terminated | Nov 10, 2006 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT01397734 | Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) | Phase 1 | terminated | Jul 20, 2011 | Beth Israel Deaconess Medical Center | Lack of enrollment and limited funding | Enrollment / accrual |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00907517 | Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute… | Phase 1 | terminated | May 22, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With… | Phase 2 | terminated | Jul 24, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Funding was unavailable to complete the study as originally planned. | Funding |
| NCT01451437 | Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute… | Phase 1 | terminated | Oct 13, 2011 | Merck Sharp & Dohme LLC | The study was terminated early due to business reasons. | Sponsor / business decision |
| NCT00245115 | Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia | Phase 1 | terminated | Oct 27, 2005 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Expiration of study supply | Drug supply |
| NCT02632903 | Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in… | Phase 2 | withdrawn | Dec 17, 2015 | Children's Hospital of Eastern Ontario | While the clinical need for and the scientific merit remain valid, this regulated drug trial was… | Funding |
| NCT00415857 | Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With… | Phase 2 | terminated | Dec 25, 2006 | M.D. Anderson Cancer Center | Vaccine sponsor ceased operations. | Other (stated, no rule matched) |
| NCT00356928 | Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies | Phase 1 | terminated | Jul 27, 2006 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Poor accrual | Enrollment / accrual |
| NCT01588951 | Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior | Phase 2 / Phase 3 | terminated | May 1, 2012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low accrual | Enrollment / accrual |
| NCT02351037 | Study of Ibrutinib in Subjects With Acute Myeloid Leukemia | Phase 2 | terminated | Jan 30, 2015 | Pharmacyclics LLC. | Study data do not support development in AML. | Other (stated, no rule matched) |
| NCT01490775 | Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib)… | N/A | terminated | Dec 13, 2011 | Rex Cancer Center, Raleigh, NC | Study was terminated due to lack of funding | Funding |
| NCT01490983 | Telemonitoring Study - for Chronic Myeloid Leukemia (CML) | N/A | terminated | Dec 13, 2011 | Rex Cancer Center, Raleigh, NC | Terminated due to lack of funding | Funding |
| NCT00104806 | Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With… | Phase 2 | terminated | Mar 4, 2005 | Wake Forest University Health Sciences | sponsor discontinues support | Other (stated, no rule matched) |
| NCT01598025 | Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an… | N/A | terminated | May 15, 2012 | Memorial Sloan Kettering Cancer Center | Closed due to poor accrual | Enrollment / accrual |
| NCT00900445 | Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk… | — | withdrawn | May 12, 2009 | Children's Oncology Group | not stated | Not stated |
| NCT03086252 | Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study | N/A | withdrawn | Mar 22, 2017 | Emory University | Slow accrual | Enrollment / accrual |
| NCT01795924 | Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia…(AML/MDS) | Phase 1 / Phase 2 | terminated | Feb 21, 2013 | Biosuccess Biotech Co., Ltd. | Difficulty of patient enrollment | Enrollment / accrual |
| NCT01037764 | Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic…(AHCTALL) | Phase 2 | terminated | Dec 23, 2009 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01761682 | Acute Lymphoblastic Leukemia Registry at Asan Medical Center | — | terminated | Jan 7, 2013 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01761695 | Chronic Myelod Leukemia Registry at Asan Medical Center | — | terminated | Jan 7, 2013 | Asan Medical Center | The PI resigned the institute. The rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT02428517 | Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia…(ATLAS2015) | — | terminated | Apr 28, 2015 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood… | Phase 2 | terminated | Dec 10, 2012 | Weill Medical College of Cornell University | Slow accrual | Enrollment / accrual |
| NCT01910428 | L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult… | Phase 1 | terminated | Jul 29, 2013 | ERYtech Pharma | Sponsor decision based off site/PI feedback about | Sponsor / business decision |
| NCT02472626 | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating… | Phase 1 / Phase 2 | withdrawn | Jun 16, 2015 | Wake Forest University Health Sciences | Drug Supply Issues | Drug supply |
| NCT01548911 | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | Phase 2 | withdrawn | Mar 8, 2012 | Wake Forest University Health Sciences | not stated | Not stated |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | Phase 1 / Phase 2 | terminated | Jan 15, 2010 | Everett Meyer | Safety | Safety / toxicity |
| NCT02204722 | A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients(IDEAL) | Phase 4 | terminated | Jul 30, 2014 | Dong-A ST Co., Ltd. | Sponsor's decision to halt the study. | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Nov 1, 2018source: clinicaltrials